A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
A high-throughput platform would greatly facilitate coronavirus disease 2019 (COVID-19) serological testing and antiviral screening. To address this, Shi and colleagues present a high-throughput nanoluciferase severe respiratory syndrome coronavirus 2 (SARS-CoV2-Nluc), and show that it has potential...
Main Authors: | Xuping Xie, Antonio E. Muruato, Xianwen Zhang, Kumari G. Lokugamage, Camila R. Fontes-Garfias, Jing Zou, Jianying Liu, Ping Ren, Mini Balakrishnan, Tomas Cihlar, Chien-Te K. Tseng, Shinji Makino, Vineet D. Menachery, John P. Bilello, Pei-Yong Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-10-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-020-19055-7 |
Similar Items
-
Author Correction: A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
by: Xuping Xie, et al.
Published: (2021-06-01) -
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
by: Antonio E. Muruato, et al.
Published: (2020-08-01) -
Author Correction: A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
by: Antonio E. Muruato, et al.
Published: (2021-06-01) -
A nanoluciferase biosensor to investigate endogenous chemokine secretion and receptor binding
by: Carl W. White, et al.
Published: (2021-01-01) -
Evasion of Type I Interferon by SARS-CoV-2
by: Hongjie Xia, et al.
Published: (2020-10-01)